Welcome to our dedicated page for Biomx news (Ticker: PHGE), a resource for investors and traders seeking the latest updates and insights on Biomx stock.
BiomX Inc. (PHGE) news is centered on the company’s transition from a legacy phage therapy profile toward defense, security, critical infrastructure, and first-response technologies. Recent company announcements focus heavily on Zorronet, an AI defense technology subsidiary that develops command-and-control, computer vision, and autonomous surveillance systems.
PHGE news can include acquisition updates, material agreements, customer deployments, and operating details tied to Zorronet and DFSL. Zorronet-related coverage has included AI command-and-control software, secure on-premise and hybrid C5ISR deployments, mobile field-operator tools, and the use of cameras, sensors, drones, and IoT devices in integrated security environments.
Infrastructure and government-related items are also important for BiomX coverage. Company disclosures have discussed Zorronet’s work with Israel Railways, contracts with the Israel Defense Forces, and engagements involving government customers, Tier-1 OEMs such as Elbit Systems, and international clients. DFSL adds another news angle through LADAR-based detection systems for perimeter security, critical infrastructure, and counter-UAS markets.
BiomX news may also include SEC filing events, shareholder votes, governance changes, capital-structure disclosures, and operating results. Because the company has disclosed substantial doubt about its ability to continue as a going concern, financing and liquidity-related disclosures are also material to PHGE coverage. For investors tracking PHGE, the main news themes are defense technology acquisitions, operational deployments, critical infrastructure agreements, and the company’s remaining phage therapy background.
BiomX (NYSE American: PHGE) received a March 25, 2026 notice that it does not meet NYSE American stockholders' equity minimums in Sections 1003(a)(i)-(iii). The company must submit a compliance plan by April 24, 2026 to regain compliance by September 25, 2027.
The Notice does not affect current listing or trading and the company previously disclosed a going concern paragraph in its 2025 audited financial statements.
BiomX (NYSE: PHGE) launched X Security & Defense LTD. in Israel on March 26, 2026 and will finance 2026 operations with over $3 million from internal funds. The company signed a non‑binding LOI for exclusive Israel distribution of an advanced aerial firefighting drone system.
BiomX aims to commercialize security, defense and first‑response technologies amid growing UAV emergency markets (UAV emergency responders: $3.2B 2023 → $9.6B 2032; firefighting drones: $1.8B 2023 → $4.5B 2032) and cites Israeli government emergency budgets exceeding $500 million.
BiomX (NYSE American: PHGE) CEO Michael Oster outlined a strategic and financial reset on March 19, 2026, aimed at stabilizing finances, simplifying capital structure, and unlocking future growth.
Key action: warrants from a December 2025 investment were amended to a one-year exercise period with an $1.00 exercise price, per the Form 8-K. Management is cutting non-essential costs, closing a Maryland facility, engaging banks and investors, and exploring repositioning toward defense-related opportunities.
BiomX (NYSE American: PHGE) announced on March 9, 2026 the appointment of Michael Oster as Chief Executive Officer and David Rokach as Chief Financial Officer to support the company’s next growth phase. Both executives bring senior experience in M&A, corporate strategy, finance, and capital markets.
BiomX is a clinical-stage company developing natural and engineered phage therapies targeting harmful bacteria in chronic diseases; the new leaders will focus on execution, capital strategy, and investor engagement.
BiomX (NYSE American: PHGE) issued a statement on January 27, 2026 addressing recent unusual trading in its common stock. The company said it is not aware of any undisclosed material developments in its business or affairs that would explain the activity.
BiomX noted that NYSE American contacted the company per usual practice and requested this statement. The company indicated it does not intend to provide further comment about market speculation or trading activity.
BiomX (NYSE American: PHGE) announced a private placement expected to raise approximately $3.0 million in gross proceeds on December 29, 2025. The company said proceeds will support assessment of opportunities to advance BX011 and continued evaluation of strategic alternatives. H.C. Wainwright & Co. served as exclusive placement agent. Amounts are before placement agent fees and offering expenses.
BiomX (NYSE American: PHGE) announced on December 8, 2025 that it will discontinue the Phase 2b trial of nebulized phage therapy BX004 in cystic fibrosis after an internal review and recommendations from the independent Data Monitoring Committee following unusually high rates of adverse events.
The company said it will implement cost‑cutting measures, including a significant workforce reduction, and review strategic alternatives while refocusing development efforts on its bacteriophage program BX011 for Staphylococcus aureus diabetic foot infections, subject to available resources.
BiomX (NYSE American: PHGE) said the FDA is continuing to evaluate the nebulizer device used in its BX004 Phase 2b cystic fibrosis trial and the company is working with the device manufacturer to provide requested information to lift the clinical hold. An independent Data Monitoring Committee (DMC) completed a safety review after adverse events and recommended the study continue with adjusted dosing. BiomX will update the protocol and now expects topline results in Q2 2026, with U.S. enrollment to resume once device questions are resolved.
BiomX (NYSE:PHGE) will effect a 1-for-19 reverse stock split of its common stock, to trade on a split-adjusted basis when markets open on November 25, 2025. The company will file a Certificate of Amendment in Delaware and the new CUSIP after the split will be 09090D 509.
The split was approved by stockholders on October 16, 2025 and the Board fixed the final ratio on November 13, 2025. Outstanding shares are expected to be reduced from approximately 29,006,165 to approximately 1,526,640, with proportional adjustments to equity awards, warrants, convertible preferred stock and plan share pools. No fractional shares will be issued; holders entitled to fractions will be rounded up to the next whole share. Recordholders with certificates will receive instructions from Continental Stock Transfer & Trust Company; street-name holders need take no action.
BiomX (NYSE:PHGE) reported third quarter 2025 results and clinical updates on Nov 12, 2025. Key clinical points: positive FDA feedback on BX011 (S. aureus in diabetic foot infections) with a planned Phase 2a and FDA guidance outlining potential Phase 3 pathways for BX004 (P. aeruginosa in cystic fibrosis). The FDA has placed a U.S. clinical hold on the BX004 Phase 2b trial related to a third-party nebulizer; enrollment and dosing outside the U.S. continue and U.S. feedback is expected imminently. The company expects topline Phase 2b results in Q1 2026.
Financial highlights: cash and restricted cash $8.1M (Sept 30, 2025), sufficient to fund operations into Q1 2026; R&D $6.1M and G&A $2.4M in Q3; net loss $9.2M in Q3. Net cash used in operations was $22.0M for the nine months ended Sept 30, 2025.